未登录

D

Declan Noone

university of milan

H指数:19

被引数:1,110

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Test-retest reliability of a mobile application of the patient reported outcomes burdens and experiences (PROBE) study

IF3

2024-03-041

PRE

Accreditation model of European Haemophilia Centres in the era of novel treatments and gene therapy

新型治疗和基因治疗时代欧洲血友病中心的认证模式

IF3

2023-10-116

PRE

Hemophilia gene therapy: first, do no harm

血友病基因治疗: 第一，无害

JOURNAL OF THROMBOSIS AND HAEMOSTASIS

IF5

2023-09-0113

OAAI

Hemorrhagic and thrombotic adverse events associated with emicizumab and extended half-life factor VIII replacement drugs: EudraVigilance data of 2021

JOURNAL OF THROMBOSIS AND HAEMOSTASIS

IF5

2023-03-0122

OAAI

Humanistic burden of problem joints for children and adults with haemophilia

IF3

2022-12-279

OA

Association of factor expression levels with annual bleeding rate in people with haemophilia B

IF3

2022-11-046

OA

Relationship between bleeding episodes, health-related quality of life and direct costs in adults with severe haemophilia A: Secondary analyses from the CHESS study

IF3

2022-06-303

OA

European principles of care for physiotherapy provision for persons with inherited bleeding disorders: Perspectives of physiotherapists and patients

IF3

2022-05-045

OA

Assessing the value of orphan drugs using conventional cost-effectiveness analysis: Is it fit for purpose?

ORPHANET JOURNAL OF RARE DISEASES

IF3.5

2022-04-0521

OAAI

Preparing for tomorrow: Defining a future agenda

IF3

2022-03-227

PRE

Gene therapy of hemophilia: Hub centres should be haemophilia centres: A joint publication of EAHAD and EHC

IF3

2022-03-0914

PRE

Hemophilia treatment in 2021: Choosing theoptimal treatment using an integrative, patient-oriented approach to shared decision-making between patients and clinicians

IF5.7

2022-03-0124

OAAI

Eliminating Panglossian thinking in development of AAV therapeutics

MOLECULAR THERAPY

IF12

2021-12-0111

OAAI

Recombinant factor IX-Fc fusion protein in severe hemophilia B: Patient-reported outcomes and health-related quality of life

RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS

IF3.4

2021-10-015

OAAI

Delivery of AAV-based gene therapy through haemophilia centres-A need for re-evaluation of infrastructure and comprehensive care: A Joint publication of EAHAD and EHC

通过血友病中心提供基于AAV的基因治疗-需要重新评估基础设施和全面护理: eahand和EHC的联合出版物

IF3

2021-09-2238

OA

Evaluation of the sexual health in people living with hemophilia

IF3

2021-09-192

PREAI

European principles of care for women and girls with inherited bleeding disorders

欧洲遗传性出血性疾病妇女和女孩的护理原则

IF3

2021-08-0337

OAAI

Clinical attributes and treatment characteristics are associated with work productivity and activity impairment in people with severe haemophilia A

IF3

2021-07-1714

OAAI

Converting factor and nonfactor usage into a single metric to facilitate benchmarking the resources consumed for haemophilia care across jurisdictions and over time

IF3

2021-06-174

PREAI

Vaccination against COVID-19: Rationale, modalities and precautions for patients with haemophilia and other inherited bleeding disorders

IF3

2021-03-029

OAAI